VALARTH See Abbott India in the appOpen in app
ABBOTINDIA · NSE · Pharmaceuticals

Abbott India Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Mid Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
fair low confidence No valuation within 120 days; P/E 34.2 vs peers 39.3 (8th of 23); P/B 11.5 vs peers 4.8 (23rd of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Abbott India's share price today?

Abbott India last traded at ₹25,790.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.8% on the day, down 13.3% over a year. Its 52-week range is ₹25,135 to ₹30,655. The live price is in the app.

₹25,790.00 −0.8% today
−13.3% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range12% of the way up
Low ₹25,135High ₹30,655

What is Abbott India's market cap?

Abbott India's market capitalisation is about ₹55,250 crore: what it would cost to buy every share at today's price. That makes it the 85th largest mid cap company we cover.

₹55,250 Cr Mid Cap85th largest mid cap company
Mid Cap means the companies ranked 101 to 250 by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: ABBOTINDIA
ISIN
INE358A01014
Cap bucket
Mid Cap, 85th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2010
Futures and options
Not traded

Is Abbott India overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 34.2 vs peers 39.3 (8th of 23); P/B 11.5 vs peers 4.8 (23rd of 25).

Valuation

Latest price and trailing 12 months
P/E 34.22
vs peers 39.3 · 8th of 23
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 11.54
vs peers 4.8 · 23rd of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹55,250 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield Not available
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 0.45
vs peers 3.3 · 3rd of 19
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 1.92
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Abbott India a quality business?

Quality score 72.5, 1st of 24 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 72.5
vs peers 53.2 · 1st of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 34.5%
vs peers 14.8% · 2nd of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 43.8%
vs peers 16.5% · 2nd of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 22.1%
vs peers 13.8% · 3rd of 24
Profit after everything, as a share of revenue. Learn more →
EPS Not available
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Abbott India made money for shareholders?

Mixed: −13.3% over one year and +5.7% a year over five years.

Shareholder returns

1-year return −13.3%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +5.7% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Yes
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−0.9%
1M
−0.5%
3M
−5.1%
6M
+1.1%
1Y
−13.3%
3Y
+6.6%
5Y
+5.7%

Does Abbott India pay a dividend?

Abbott India last paid ₹131.00 a share, ex-dividend 24 Jul 2026; nothing in the past 12 months counts toward a yield.

Dividends

Per share, by ex-dividend date
24 Jul 2026 · Special₹131.00
24 Jul 2026 · Final₹525.00
25 Jul 2025 · Final₹475.00
19 Jul 2024 · Final₹410.00
21 Jul 2023 · Special₹145.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Abbott India growing?

Revenue 3 years 9.4% a year; profit 3 years 17.8% a year; revenue 5 years 7.9% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 9.4% a year
vs peers 14.3% · 17th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 17.8% a year
vs peers 21.6% · 13th of 20
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 7.9% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 15.1% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 17.8% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 17.6% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history -29.2%
vs peers 16.7% · 2nd of 19
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Abbott India do last quarter?

Abbott India reported revenue of ₹1,814 Cr, up 9.7% on a year earlier and a net profit of ₹429 Cr, up 17.8% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹1,814 Cr
+9.7% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹429 Cr
+17.8% on a year earlier
What was left for shareholders after every cost and tax.

How does Abbott India compare with its peers?

Compared with 24 Pharmaceuticals; 8th of 23 on P/E; 1st of 24 on quality score.

Compared with 24 Pharmaceuticals

24 companies

Abbott India against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Abbott India Ltd₹55,250 Cr34.211.534.5%43.8%−13.3%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Alkem Laboratories Ltd₹63,118 Cr29.34.517.3%18.8%−3.9%
Biocon Ltd₹56,942 Cr102.82.20.9%1.6%—
Peer median—39.34.814.8%16.5%+41.0%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Abbott India?

Abbott India is held by promoters 75.0%, foreign institutions 0.4%, domestic institutions 8.8%.

Shareholding pattern

Latest filing, percent of shares
Promoters75.0%
The founders and controlling group.
Foreign institutions0.4%
Overseas funds investing through the FPI route.
Domestic institutions8.8%
Indian insurers, banks, pension and mutual funds together.
Mutual funds7.4%
Indian mutual fund schemes; part of domestic institutions.
Retail and others13.3%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Abbott India?

7 analysts cover Abbott India, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

7 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Abbott India do and what is it sensitive to?

Abbott India Limited sells pharmaceuticals in India across therapeutic areas including Gastroenterology, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty. Sensitive to: generic competition and pricing.

Business-model card

FY2025 · 36 verified
2Revenue
4Channels
2Regulators
3Reg. dependencies
4Sensitivities
5Costs
3Geographies

Abbott India Limited sells pharmaceuticals in India across therapeutic areas including Gastroenterology, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty. It sells mainly to distributors and stockists, plus healthcare professionals, hospitals, government institutions, pharmacists and consumers, and earns through product sales.

Revenue engine

2 verified
Pharmaceuticals (single business segment) (100.0%)
Manufacturing, marketing, sale and distribution of pharmaceuticals; the company reports one segment, and its turnover is 100% from this activity.
Branded products across key therapeutic areas
Sales of branded products in Gastroenterology, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty. Interpretation: revenue is spread across these areas and sold through the sales force and distributors.

Customers & channels

4 verified
Distributors and stockists (96.7%)
Dealers and distributors account for most sales, so distributor relationships carry the volume. Interpretation: the sales channel depends on this group.
Customer groups named in the filing
Customers include distributors, stockists, healthcare professionals, hospitals, government institutions, pharmacists, and consumers.
No single customer above 10% of revenue
The filing states that no individual customer contributes more than 10% of total revenue, so concentration risk sits in the distributor channel rather than any one customer.
1 more statement
Advance payment and collection-on-delivery terms
Significant sales are made against advance payment or collection on delivery. Interpretation: this limits receivable exposure for these sales.

Regulators

2 verified
Ministry of Health and the Union Government (Drugs and Cosmetics Rules)
Governs what drugs may be sold without prescription. A proposed amendment would allow OTC retail sale of listed drugs.
Reserve Bank of India (foreign exchange compounding)
The RBI is handling a compounding application filed by the company. The filing does not state the subject matter beyond the compounding process. Interpretation: this is a foreign exchange regulatory matter.

Regulatory dependencies

3 verified
Proposed OTC distribution policy
Interpretation: if the draft is adopted, listed categories could sell through non-prescription retail, which would add a sales channel for the company's products in those categories.
Tighter clinical trial and drug approval rules
The filing says these rules may create short-term headwinds and strengthen the industry in the long term. Interpretation: revenue timing for new launches would be affected.
Patent expiry of drugs
Interpretation: when drugs go off-patent, generic competition rises and branded pricing and volume can be affected.

Sensitivities

4 verified
Generic competition and pricing
Direction: when competition in generics rises, pricing pressure increases. The filing states the pressure but gives no price elasticity.
Interest rates on deposits
Investments are primarily fixed-rate. Interpretation: rate changes have limited effect on the carrying value of deposits, though interest income from fixed deposits (256.63 crore FY2024-25) is a separate income line.
USD exchange rate
Direction: a 1% rise in USD reduces profit before tax by 1.49 crore per the sensitivity table, and a 1% fall raises it by the same amount. Unhedged exposure is stated as not material.
1 more statement
Expired product returns
Interpretation: returns are mainly expired or near-expiry stock, so higher returns reduce net revenue through the returns provision.

Cost inputs

5 verified
Purchases from trading houses (81.3%)
Most purchases are routed through trading houses, and the top 10 account for most of that volume.
Related-party purchases (15.6%)
Share of total purchases made from related parties.
Imports of raw materials, finished goods and capital goods
Foreign exchange used for these imports was 604.17 crore in the year.
2 more statements
Active Pharmaceutical Ingredients (industry)
Interpretation: the filing describes import reliance for APIs at industry level; it does not state the company's own API sourcing.
Inputs sourced directly from MSMEs
Share of input material purchases sourced directly from MSMEs or small producers.

Geographies

3 verified
India (domestic)
Sales are substantially in the domestic market; the company operates in 28 States and 8 Union Territories.
Exports (1.2%)
Share of total turnover from exports.
Export markets
The international locations named in the filing are a small export market.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (12 Aug 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedFirst Half FY2026 results filed.
  6. Results filedQ1 FY2026 results filed.
  7. Corporate actionDividend - Rs 475 Per Share.
  8. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsWATCH on 30 of 30 flags judged; 2 red.
  • Data gapsDividend yield, Business quality, EPS: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓201 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 36 verified

Questions people ask

What is Abbott India's share price today?

Abbott India last traded at ₹25,790.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.8% on the day, down 13.3% over a year. Its 52-week range is ₹25,135 to ₹30,655. The live price is in the app.

What is Abbott India's market cap?

Abbott India's market capitalisation is about ₹55,250 crore: what it would cost to buy every share at today's price. That makes it the 85th largest mid cap company we cover.

Is Abbott India Ltd a large cap, mid cap or small cap?

Abbott India Ltd (ABBOTINDIA) is a mid cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Abbott India Ltd's P/E ratio?

34.22, vs peers 39.3 · 8th of 23. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Abbott India Ltd overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 34.2 vs peers 39.3 (8th of 23); P/B 11.5 vs peers 4.8 (23rd of 25).

How does Abbott India Ltd make money?

Abbott India Limited sells pharmaceuticals in India across therapeutic areas including Gastroenterology, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty. It sells mainly to distributors and stockists, plus healthcare professionals, hospitals, government institutions, pharmacists and consumers, and earns through product sales.

Who are Abbott India Ltd's peers?

Compared with 24 Pharmaceuticals: Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd, Mankind Pharma Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Abbott India do last quarter?

Abbott India reported revenue of ₹1,814 Cr, up 9.7% on a year earlier and a net profit of ₹429 Cr, up 17.8% in the Jun 2026 quarter.

Who owns Abbott India?

Abbott India is held by promoters 75.0%, foreign institutions 0.4%, domestic institutions 8.8%.

Does Abbott India pay a dividend?

Abbott India last paid ₹131.00 a share, ex-dividend 24 Jul 2026; nothing in the past 12 months counts toward a yield.

What do analysts say about Abbott India?

7 analysts cover Abbott India, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Abbott India, and 6,621 other companies, with 212 filters and the full peer tables

See Abbott India in the app →See pricing